Literature DB >> 2478779

Effect of verapamil on systemic and brachial artery hemodynamics in normal humans: comparison with effect of atenolol.

L Vanhees1, R Fagard, A Amery.   

Abstract

To clarify the hemodynamic effects of verapamil, we investigated in normal volunteers the effects of 4-day treatment with verapamil (240 mg/day) on left ventricular function and on systemic and brachial artery haemodynamics, in comparison with the effects of placebo and atenolol (100 mg/day). Left ventricular structure and function was evaluated by echocardiography, systemic hemodynamics were assessed by pulsed Doppler velocimetry of the ascending aorta, and brachial artery hemodynamics were assessed pulsed Doppler velocimetry of the brachial artery. Verapamil decreased systemic and brachial artery vascular resistance (p less than 0.05), increased cardiac output (CO, p less than 0.01) and brachial flow (p = 0.054), and did not affect blood pressure (BP) and heart rate (HR). In contrast, atenolol decreased BP, HR, and CO (p less than 0.001) but did not significantly affect brachial flow and systemic and brachial artery vascular resistance. We conclude that short-term administration of verapamil in normal humans produces systemic and brachial artery vasodilatation, with a reflex increase of stroke volume but not of HR.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2478779     DOI: 10.1097/00005344-198910000-00017

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

1.  Non invasive study of systemic and regional haemodynamic and cardiac effects of a new calcium antagonist, SR 33557, in healthy volunteers.

Authors:  E Bellissant; C Thuillez; R Kechrid; P Duhaze; J F Giudicelli
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Verapamil 240 SR versus verapamil 120 SR in arterial hypertension. A randomized double-blind, placebo-controlled study with 24-hour ambulatory blood pressure monitoring.

Authors:  L Corea; M Bentivoglio; S Berioli; C Bianchini; K Savino; M Sardina
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.